Plus Therapeutics
Manufacturing · Texas, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
6420 Levit Green Blvd Ste 210, Houston, ...Phone Number
(210) 974-6900Website
www.plustherapeutics.comRevenue
$5.2 MillionStock Symbol
PSTVIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Plus Therapeutics
Plus Therapeutics (PSTV on Nasdaq) is a U.S. clinical-stage pharmaceutical company, backed by talented executives and a nationwide network of scientists, engineers, and physicians. With a hybrid virtual drug development model, the company is well-positioned to be capital efficient, enhance operational efficiencies, decrease costs, and accelerate product development. Plus Therapeutics is headquartered in Houston, Texas, with additional laboratories and state-of-the-art clean rooms that enable the company to undertake key development, manufacturing, and preclinical activities. The company's location provides it with many strategic advantages, including proximity to world-class cancer institutions and researchers as well as the ability to qualify and apply for funding through the Cancer Prevention and Research Institute of Texas (CPRIT).Explore more
Plus Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Plus Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Plus Therapeutics recently announced quarterly report
Check out if Plus Therapeutics is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Plus Therapeutics launches new products
Plus Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Plus Therapeutics had a recent Job posting/layoffs
Check if Plus Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Plus Therapeutics has new funding data
Congratulate Masked Content for being promoted to Masked Content at Plus Therapeutics
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined Plus Therapeutics as Masked Content
Find 3 more new buyers
Compare Similar Companies to Plus Therapeutics
Compare insights from companies similar to Plus Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Plus Therapeutics
$5.2M
11-50
Public
$35.6M
2019
RB
Russell BradleyPresident and General Manager, CNSide Diagnostics
Company Profile Activity
Activity Insights
Plus Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Plus Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Plus Therapeutics.
Plus Therapeutics financials insights
Gather financial insights about Plus Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Grant
$17.6M
2024
Share Placement
$18M
Plus Therapeutics Tech Stack
A closer look at the technologies used by Plus Therapeutics
Most Recent Scoops
Earnings
Earnings, Finance
Open Position
New Hire
Executive Move
Executive Moves, New Hire
New Hire
Executive Move
Executive Moves, New Hire
Event
Person-Based
Events, Medical Research, Pharmaceuticals, Podcast
Plus Therapeutics News & Media
Plus Therapeutics and Genomic Testing Cooperative Partner to Integrate Next-Generation Sequencing Into the CNSide® CSF Assay Platform
Collaboration expected to deliver hundreds of DNA and RNA biomarkers from a single CSF specimen — directly aligned with the updated NCCN Guidelines® (Version 2.2026), which now recognize CSF circulating tumor cells alongside tumor-derived DNA and broaden the leptomeningeal treatment algorithm from “CSF cytology” to “CSF analysis” Collaboration expected to deliver hundreds of DNA and RNA biomarkers from a single CSF specimen — directly aligned with the updated NCCN Guidelines® (Version 2.2026), wPlus Therapeutics Highlights NCCN CNS Cancers Guidelines Update and Reinforces Clinical Role of CNSide® in Leptomeningeal Metastases Monitoring
Updated NCCN language continues to support CSF analysis in the diagnosis and management of leptomeningeal metastases, including CSF cytology follow-up every 4 to 8 weeks for patients receiving intrathecal therapy, to enable longitudinal patient monitoring Updated NCCN language continues to support CSF analysis in the diagnosis and management of leptomeningeal metastases, including CSF cytology follow-up every 4 to 8 weeks for patients receiving intrathecal therapy, to enable longitudinal patientPlus Therapeutics, Inc. (PSTV) Discusses Rebranding and Integrated CNS Oncology Platform Strategy Transcript
Plus Therapeutics, Inc. (PSTV) Discusses Rebranding and Integrated CNS Oncology Platform Strategy June 30, 2026 8:30 AM EDTCompany ParticipantsMarc Hedrick...Plus Therapeutics Provides Mid-Year Business Update Including Corporate Rebranding
Plus Therapeutics to become Cerenome, to trade under new Nasdaq ticker CNSY on August 3, 2026
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Plus Therapeutics
Sign Up For FreeTo access detailed company insights
Plus Therapeutics (PSTV on Nasdaq) is a U.S. clinical-stage pharmaceutical company, backed by talented executives and a nationwide network of scientists, engineers, and physicians. With a hybrid virtual drug development model, the company is well-positioned to be capital efficient, enhance operational efficiencies, decrease costs, and accelerate pr... Read More
